MEDLINE/PubMed Journal Browser Search

Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

Title: [Expression of lncRNA UCA1 in Acute Myeloid Leukemia Patients and Its Clinical Significance].
Author: Bai X, Wu YP, Li ZY, Chen XF, Wang M, Li JJ.
Journal: Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2024 Aug; 32(4):999-1004. PubMed ID: 39192389.
Abstract:
OBJECTIVE: To investigate the expression level of urothelial carcinoembryonic antigen 1 (lncRNA UCA1) in the bone marrow of acute myeloid leukemia (AML) patients, and to explore the clinical significance of lncRNA UCA1 expression level in AML patients. METHODS: Bone marrow samples of 50 AML patients were collected as experimental group, and bone marrow samples of 20 iron deficiency anemia (IDA) patients were collected as control group. The relevant clinicopathological characteristics of AML patients were collected. Real-time quantitative PCR (qRT-PCR) was used to detect the expression level of lncRNA UCA1 in the experimental and control groups, and the relationships between lncRNA UCA1 expression and clinical pathological characteristics and prognosis in AML patients were analyzed. Kaplan-Meier curves were used to analyze the effect of lncRNA UCA1 on the overall survival (OS) of AML patients; And Cox regression model was used to analyze the factors affecting the prognosis of AML patients. RESULTS: Compared with the control group, the expression level of lncRNA UCA1 was significantly elevated in patients with AML (P < 0.001); The proportion of patients with hemoglobin lower than 90 g/L in lncRNA UCA1 high expression group was significantly higher than that in lncRNA UCA1 low expression group (P =0.004); The expression level of lncRNA UCA1 was higher in M1, M2, and M4 subtypes, while it was lower in M0 and M5 subtypes, and the difference was statistically significant (P =0.009). There were no significant difference in sex, age, white blood cell (WBC) count, platelet (PLT) count, bone marrow blasts , chemotherapy regimen and efficacy, karyotype, gene mutation, and prognostic risk stratification between patients in UCA1 high expression group and those in UCA1 low expression group (all P > 0.05). The OS of patients with high expression of lncRNA UCA1 was significantly shorter than that of patients with low expression of lncRNA UCA1 (P =0.0229). CONCLUSION: The expression level of lncRNA UCA1 is significantly upregulated in AML patients. High expression of lncRNA UCA1 is associated with poor clinicopathological features and poor prognosis. Therefore, lncRNA UCA1 can be used as a prognostic indicator and a potential therapeutic target for AML patients. 题目: lncRNA UCA1在急性髓系白血病患者中的表达及其临床意义. 目的: 检测急性髓系白血病（AML）患者骨髓中尿路上皮癌胚抗原1（lncRNA UCA1）的表达水平，并探讨lncRNA UCA1表达水平在AML患者中的临床意义。. 方法: 收集50例AML 患者骨髓标本作为实验组和20例缺铁性贫血（IDA）患者骨髓标本作为对照组，并收集AML患者的相关临床病理特征资料。采用实时荧光定量PCR（qRT- PCR）检测lncRNA UCA1在实验组和对照组中的表达水平，并分析lncRNA UCA1在AML患者中的表达水平与临床病理特征及预后的关系。采用Kaplan-Meier曲线分析lncRNA UCA1表达水平对AML患者总体生存时间（OS）的影响；采用Cox风险回归模型分析影响AML患者预后的因素。. 结果: 与对照组相比，lncRNA UCA1表达水平在AML患者中明显升高（P < 0.001）；lncRNA UCA1高表达组中血红蛋白低于90 g/L的患者占比明显高于低表达组（P =0.004）；lncRNA UCA1在M1、M2和M4型AML患者中表达水平较高，而在M0、M5型AML患者中表达水平较低，差异具有统计学意义（P =0.009）。lncRNA UCA1高表达组患者与低表达组患者的性别、年龄、WBC计数、PLT计数、骨髓原始细胞比例、化疗方案及疗效、核型、基因突变及预后风险分层的差异均无统计学意义（均P >0.05）；lncRNA UCA1高表达组患者的OS较低表达组患者显著缩短（P =0.0229）。. 结论: lncRNA UCA1表达水平在AML患者中明显上调，其高表达与较差的临床病理特征及不良预后相关，可作为判断AML患者预后的指标和潜在的治疗靶点。.

[Abstract] [Full Text] [Related] [New Search]